New index that tracks more diseases across many countries is going to be re-launched by the faculty at Binghamton University, State University of New York who previously launched the Global Health Impact Index.
A re-launch event, "The Global Health Impact Project: Progress Towards the Sustainable Development Goals," will takes in the Robertston Hall at the Liechtenstein Institute of Self-Determination at Princeton University. A new website and models will be introduced, and two roundtable discussions will follow.
The Global Health Impact Index was first launched at the World Health Organization in Geneva in 2015 by Binghamton University Associate Professor of Philosophy Nicole Hassoun.
The new index confronts these uncertainties, and is a first step towards momentous change, said Hassoun. The new index also considers drugs' impacts over time, across countries and diseases, and assesses different parts of the pharmaceutical supply chain - showing how generics companies contribute to getting drugs to the people who need them.
"A lot of attention has been paid in determining the need for different drugs, but the Global Health Impact Index actually addresses the impact that these drugs are having globally," said Hassoun. "Having this information readily available could help improve the overall delivery of drugs and help save millions of lives."
The index looks at three things: the need for several important drugs for tuberculosis, HIV/AIDS, malaria and multiple neglected tropical diseases; the drugs' effectiveness; and the number of people who can access these drugs. Each company's score is the sum of its drugs' impacts.
According to the index, the companies who came up with or hold the patent on drugs having the most impact on focus diseases are:
The manufacturers and distributors who had the largest drug impact scores on the index are:
The countries who had the most need alleviated by various drugs are:
The diseases that have the largest global burden are:
Previously, the Global Health Impact Index utilized a preliminary model to evaluate the impact of medications used to treat HIV/AIDS, malaria and tuberculosis. The Global Health Impact project has greatly expanded its scope to include a multitude of other diseases plaguing both developing and developed countries. The new models include a variety of neglected tropical diseases (NTDs) that primarily impact low-impact communities around the world. While previous indexes have only measured the need for different drugs worldwide, the Global Health Impact Index is the first to measure the impact of these drugs.
"As the world moves forward in confronting detrimental diseases, and the social and economic ramifications that they bring," added Hassoun, "it is essential that we continuously evaluate the impacts of various medications, to accommodate the constantly changing scope of global health, whether that be the research and invention of new prevention and treatment plans, or the changing effects of disease."